Dana-Farber to Expand Advanced Cancer Care with Installation of Mevion’s Compact Proton Therapy System
The landscape of cancer treatment continues to evolve as healthcare providers increasingly adopt advanced technologies designed to improve patient outcomes while minimizing treatment-related side effects. In a major development for radiation oncology, Mevion Medical Systems announced that the renowned Dana-Farber Cancer Institute will install the innovative MEVION S250-FIT Proton Therapy System™ at its Longwood Medical Area campus in Boston. The move represents a significant step forward in expanding access to state-of-the-art proton therapy for both pediatric and adult cancer patients.
The installation will allow Dana-Farber to integrate proton therapy directly into its multidisciplinary cancer care environment, further strengthening the institute’s ability to provide comprehensive and highly specialized treatment options. Pediatric patients receiving care through the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center are also expected to benefit from the addition of this advanced radiation therapy platform.
Proton therapy has become an increasingly important component of modern cancer treatment due to its ability to deliver highly targeted radiation doses to tumors while reducing damage to nearby healthy tissues. Unlike conventional radiation therapy, proton therapy minimizes unnecessary radiation exposure beyond the tumor site, helping reduce side effects and long-term complications. This precision is particularly important when treating cancers located near sensitive organs or in pediatric patients whose bodies are still developing.
According to Dr. Peter F. Orio, Chair of the Department of Radiation Oncology at Dana-Farber, the integration of proton therapy into the institute’s clinical environment reflects a commitment to offering patients the most advanced treatment technologies available.
“Proton therapy is a critical tool in modern radiation oncology and cancer care, delivering the precision needed to eradicate malignant tumors while sparing surrounding healthy tissues and minimizing side effects,” Dr. Orio stated. “We are eager to make state-of-the-art proton therapy available to our pediatric and adult patients, bringing the right treatment to the right patient, exactly when and where it is needed most.”
National cancer treatment guidelines increasingly recognize proton therapy as an effective option for select cancer types, especially in cases where reducing radiation exposure to healthy tissue is essential. Pediatric cancers, brain tumors, spinal tumors, head and neck cancers, and cancers located near critical organs often benefit from proton therapy’s highly focused approach.
For young cancer patients in particular, minimizing exposure to surrounding tissues can significantly reduce the risk of developmental complications, secondary cancers, and long-term health issues that may arise years after treatment. By incorporating proton therapy into its Longwood campus, Dana-Farber aims to enhance the quality of care while expanding access to this specialized treatment modality.
Gerard Walsh, Vice President of Radiation Oncology at Dana-Farber, emphasized that the new installation aligns with the organization’s broader mission to deliver comprehensive cancer care through innovation and patient-centered treatment strategies.
“By adding proton therapy to our Longwood campus, we are expanding the range of advanced treatments we can offer in one location,” Walsh explained. “This investment reflects our commitment to ensuring patients have access to the most effective technologies available.”
A key aspect of the announcement is the deployment of the MEVION S250-FIT Proton Therapy System™, which represents a new generation of compact proton therapy solutions designed to overcome many of the traditional barriers associated with proton therapy installations.
Historically, proton therapy centers have required massive facilities, extensive infrastructure, and substantial financial investment due to the size and complexity of conventional proton therapy equipment. These requirements have limited the availability of proton therapy to only a relatively small number of specialized cancer centers around the world.
Mevion’s FIT platform was specifically developed to address these challenges by enabling proton therapy systems to fit within existing linear accelerator vaults commonly used for conventional radiation therapy equipment. This compact design dramatically reduces the space, construction costs, and installation timelines traditionally associated with proton therapy facilities.
The compact nature of the MEVION S250-FIT system allows hospitals and cancer centers to integrate proton therapy into existing clinical settings without the need for entirely new buildings or large-scale infrastructure expansion. As a result, more healthcare institutions may be able to offer proton therapy services to patients who previously would have needed to travel long distances for treatment.
The MEVION S250-FIT system also incorporates several advanced treatment technologies aimed at improving therapeutic precision and efficiency. Among its core capabilities is Mevion’s HYPERSCAN® pencil-beam scanning technology, which supports Intensity-Modulated Proton Therapy (IMPT). IMPT enables clinicians to precisely shape and control proton beams to match the unique contours of tumors, maximizing radiation delivery to cancerous tissues while reducing exposure to nearby healthy structures.
Additionally, the system is designed to support DirectARC™ proton arc therapy, an emerging treatment approach that aligns with modern radiotherapy workflows and has the potential to further enhance treatment precision and efficiency.
Another distinctive feature of the installation involves the integration of Marie®, an upright patient positioning and imaging solution developed by Leo Cancer Care. Rather than rotating a large gantry around the patient, the Marie system rotates the patient during treatment delivery. This innovative approach fundamentally changes how radiation therapy systems can be designed and implemented.
Traditional proton therapy systems often rely on large rotating gantries that contribute significantly to the size, complexity, and cost of treatment facilities. By rotating the patient instead of the machine, the Marie system helps eliminate the need for these enormous mechanical structures, allowing for faster installations and more compact treatment environments.
The combination of Mevion’s compact proton therapy platform and Leo Cancer Care’s upright positioning technology represents a broader trend toward making advanced cancer therapies more accessible, practical, and scalable for healthcare providers worldwide.
Tina Yu, PhD, Chief Executive Officer of Mevion Medical Systems, stated that Dana-Farber’s decision to adopt the FIT system demonstrates a strong commitment to innovation and patient access.
“Dana-Farber’s decision to integrate proton therapy into its Longwood campus reflects a clear vision for innovation and patient access,” Yu said. “Our FIT system was created to bring the full benefits of proton therapy into leading hospitals without the barriers of traditional large facilities.”
The partnership between Dana-Farber and Mevion also highlights the growing demand for advanced radiation oncology technologies as cancer centers seek to improve treatment quality and patient experience. As healthcare systems increasingly focus on personalized medicine and precision oncology, technologies such as proton therapy are expected to play a larger role in cancer treatment strategies.
For patients, the availability of proton therapy within an integrated multidisciplinary care setting offers several advantages. Treatment teams can collaborate more efficiently across specialties, enabling coordinated care plans that incorporate surgery, chemotherapy, immunotherapy, and radiation oncology services within a single institution. This integrated approach may help streamline treatment timelines, improve patient convenience, and enhance overall clinical outcomes.
The installation of the MEVION S250-FIT system at Dana-Farber’s Longwood campus further reinforces Boston’s reputation as a global hub for medical innovation and cancer research. As one of the nation’s leading cancer centers, Dana-Farber continues to invest in advanced technologies that support its mission of delivering cutting-edge, patient-focused care.
The project also signals broader momentum within the healthcare industry toward expanding proton therapy access beyond traditional large-scale specialty centers. Compact and flexible proton therapy systems could potentially transform the economics and logistics of proton therapy deployment, opening the door for wider adoption in hospitals and regional cancer centers across the world.
As cancer incidence continues to rise globally, the demand for advanced, targeted, and less invasive treatment options is expected to increase significantly. Innovations like the MEVION S250-FIT Proton Therapy System™ may help bridge the gap between technological advancement and real-world patient accessibility, ensuring that more individuals can benefit from highly precise cancer treatment closer to home.
With the addition of proton therapy to its multidisciplinary treatment capabilities, Dana-Farber is positioning itself at the forefront of next-generation cancer care, offering patients access to sophisticated therapies designed to improve outcomes while minimizing the physical burden of treatment.
About Mevion Medical Systems:
Mevion Medical Systems is a leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i® and MEVION S250-FIT™ with HYPERSCAN® pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia
